Pharmacological Reviews
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     



0031-6997/06/5804-726-741$7.00
Pharmacol Rev 58:726-741, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Michalik, L.
Right arrow Articles by Wahli, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Michalik, L.
Right arrow Articles by Wahli, W.

Article

International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors

Liliane Michalik, Johan Auwerx, Joel P. Berger, V. Krishna Chatterjee, Christopher K. Glass, Frank J. Gonzalez, Paul A. Grimaldi, Takashi Kadowaki, Mitchell A. Lazar, Stephen O'Rahilly, Colin N. A. Palmer, Jorge Plutzky, Janardan K. Reddy, Bruce M. Spiegelman, Bart Staels and Walter Wahli

Center for Integrative Genomics, National Research Centre "Frontiers in Genetics," University of Lausanne, Lausanne, Switzerland (L.M., W.W.); Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France (J.A.); Merck Research Laboratories, Rahway, New Jersey (J.P.B.); Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom (V.K.C., S.O.); Division of Endocrinology, Diabetes and Hypertension, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California (C.K.G.); Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland (F.J.G.); Institut National de la Santé et de la Recherche Médicale U636, Centre de Biochimie, l'Unité de Formation et de Recherche Sciences, Université de Nice-Sophia Antipolis, Nice, France (P.A.G.); Graduate School of Medicine, University of Tokyo, Tokyo, Japan (T.K.); Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, and the Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania (M.A.L.); Biomedical Research Centre, Ninewells Hospital and Medical School, University of Dundee, Dundee, United Kingdom (C.N.A.P.); Cardiovascular Division, Harvard Medical School, and Brigham and Women's Hospital, Boston, Massachusetts (J.P.); Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois (J.A.R.); Dana-Farber Cancer Institute and Department of Cell Biology, Harvard Medical School, Boston, Massachusetts (B.M.S.); and Unité de Recherche 545, Institut National de la Santé et de la Recherche Médicale, Institut Pasteur de Lille, Lille, France (B.S.)

Abstract
Introduction
Classification of PPARs in the Nuclear Receptor Family
Chromosomal Distribution
Functional Roles
Structural Features of the Ligand-Binding Domain
Endogenous Ligands
Synthetic Modulators and Pharmacology of PPARs
Abstract

The three peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors of the nuclear hormone receptor superfamily. They share a high degree of structural homology with all members of the superfamily, particularly in the DNA-binding domain and ligand- and cofactor-binding domain. Many cellular and systemic roles have been attributed to these receptors, reaching far beyond the stimulation of peroxisome proliferation in rodents after which they were initially named. PPARs exhibit broad, isotype-specific tissue expression patterns. PPAR{alpha} is expressed at high levels in organs with significant catabolism of fatty acids. PPARbeta/{delta} has the broadest expression pattern, and the levels of expression in certain tissues depend on the extent of cell proliferation and differentiation. PPAR{gamma} is expressed as two isoforms, of which PPAR{gamma}2 is found at high levels in the adipose tissues, whereas PPAR{gamma}1 has a broader expression pattern. Transcriptional regulation by PPARs requires heterodimerization with the retinoid X receptor (RXR). When activated by a ligand, the dimer modulates transcription via binding to a specific DNA sequence element called a peroxisome proliferator response element (PPRE) in the promoter region of target genes. A wide variety of natural or synthetic compounds was identified as PPAR ligands. Among the synthetic ligands, the lipid-lowering drugs, fibrates, and the insulin sensitizers, thiazolidinediones, are PPAR{alpha} and PPAR{gamma} agonists, respectively, which underscores the important role of PPARs as therapeutic targets. Transcriptional control by PPAR/RXR heterodimers also requires interaction with coregulator complexes. Thus, selective action of PPARs in vivo results from the interplay at a given time point between expression levels of each of the three PPAR and RXR isotypes, affinity for a specific promoter PPRE, and ligand and cofactor availabilities.


Address correspondence to: Dr. Walter Wahli, Center for Integrative Genomics, University of Lausanne, Le Genopode, CH-1015 Lausanne, Switzerland. E-mail: walter.wahli{at}unil.ch




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
N. Wagner, C. Jehl-Pietri, P. Lopez, J. Murdaca, C. Giordano, C. Schwartz, P. Gounon, S. N. Hatem, P. Grimaldi, and K.-D. Wagner
Peroxisome proliferator-activated receptor {beta} stimulation induces rapid cardiac growth and angiogenesis via direct activation of calcineurin
Cardiovasc Res, July 1, 2009; 83(1): 61 - 71.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
S. E. Nissen
Pioglitazone to Reduce Restenosis After Bare-Metal Stent Placement?
J. Am. Coll. Cardiol. Intv., June 1, 2009; 2(6): 532 - 533.
[Full Text] [PDF]


Home page
GutHome page
R Marion-Letellier, P Dechelotte, M Iacucci, and S Ghosh
Dietary modulation of peroxisome proliferator-activated receptor gamma
Gut, April 1, 2009; 58(4): 586 - 593.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
Z. Zheng, H. Chen, G. Ke, Y. Fan, H. Zou, X. Sun, Q. Gu, X. Xu, and P. C.P. Ho
Protective Effect of Perindopril on Diabetic Retinopathy Is Associated With Decreased Vascular Endothelial Growth Factor-to-Pigment Epithelium-Derived Factor Ratio: Involvement of a Mitochondria-Reactive Oxygen Species Pathway
Diabetes, April 1, 2009; 58(4): 954 - 964.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
M. Teboul, F. Guillaumond, A. Grechez-Cassiau, and F. Delaunay
Minireview: The Nuclear Hormone Receptor Family Round the Clock
Mol. Endocrinol., December 1, 2008; 22(12): 2573 - 2582.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. Rieck, W. Meissner, S. Ries, S. Muller-Brusselbach, and R. Muller
Ligand-Mediated Regulation of Peroxisome Proliferator-Activated Receptor (PPAR) {beta}/{delta}: A Comparative Analysis of PPAR-Selective Agonists and All-trans Retinoic Acid
Mol. Pharmacol., November 1, 2008; 74(5): 1269 - 1277.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
P. J. Murphy
The Development of Drug Metabolism Research as Expressed in the Publications of ASPET: Part 3, 1984-2008
Drug Metab. Dispos., October 1, 2008; 36(10): 1977 - 1982.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
S. D. Conzen
Minireview: Nuclear Receptors and Breast Cancer
Mol. Endocrinol., October 1, 2008; 22(10): 2215 - 2228.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
D. F. Lehmann and B. B. Lohray
A Lesson in Moderation: Applying Pharmacodynamics to Clarify the Relationship Between Thiazolidinediones and Adverse Vascular Outcomes in Type 2 Diabetes
J. Clin. Pharmacol., August 1, 2008; 48(8): 999 - 1002.
[Full Text] [PDF]


Home page
DiabetesHome page
R. Rodriguez-Calvo, L. Serrano, T. Coll, N. Moullan, R. M. Sanchez, M. Merlos, X. Palomer, J. C. Laguna, L. Michalik, W. Wahli, et al.
Activation of Peroxisome Proliferator-Activated Receptor {beta}/{delta} Inhibits Lipopolysaccharide-Induced Cytokine Production in Adipocytes by Lowering Nuclear Factor-{kappa}B Activity via Extracellular Signal-Related Kinase 1/2
Diabetes, August 1, 2008; 57(8): 2149 - 2157.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
M. H. Liu, J. Li, P. Shen, B. Husna, E. S. Tai, and E. L. Yong
A Natural Polymorphism in Peroxisome Proliferator-Activated Receptor-{alpha} Hinge Region Attenuates Transcription due to Defective Release of Nuclear Receptor Corepressor from Chromatin
Mol. Endocrinol., May 1, 2008; 22(5): 1078 - 1092.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
N. G. Venkata, C. S. Aung, P. J. Cabot, G. R. Monteith, and S. J. Roberts-Thomson
PPAR{alpha} and PPAR{beta} Are Differentially Affected by Ethanol and the Ethanol Metabolite Acetaldehyde in the MCF-7 Breast Cancer Cell Line
Toxicol. Sci., March 1, 2008; 102(1): 120 - 128.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
D. Bishop-Bailey
Peroxisome Proliferator-Activated Receptor {beta}/{delta} Goes Vascular
Circ. Res., February 1, 2008; 102(2): 146 - 147.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Guo, J. Sarkar, K. Suino-Powell, Y. Xu, K. Matsumoto, Y. Jia, S. Yu, S. Khare, K. Haldar, M. S. Rao, et al.
Induction of Nuclear Translocation of Constitutive Androstane Receptor by Peroxisome Proliferator-activated Receptor {alpha} Synthetic Ligands in Mouse Liver
J. Biol. Chem., December 14, 2007; 282(50): 36766 - 36776.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. F. Gillespie and L. J. Gudas
Retinoic Acid Receptor Isotype Specificity in F9 Teratocarcinoma Stem Cells Results from the Differential Recruitment of Coregulators to Retinoic Acid Response Elements
J. Biol. Chem., November 16, 2007; 282(46): 33421 - 33434.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
S. Das, M. Schapira, M. Tomic-Canic, R. Goyanka, T. Cardozo, and H. H. Samuels
Farnesyl Pyrophosphate Is a Novel Transcriptional Activator for a Subset of Nuclear Hormone Receptors
Mol. Endocrinol., November 1, 2007; 21(11): 2672 - 2686.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
H. Shen, R. MacDonald, D. Bruemmer, A. Stromberg, A. Daugherty, X.-a. Li, M. Toborek, and B. Hennig
Zinc Deficiency Alters Lipid Metabolism in LDL Receptor Deficient Mice Treated with Rosiglitazone
J. Nutr., November 1, 2007; 137(11): 2339 - 2345.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
T. L. Horn, K. E. O. Torres, J. M. Naylor, M. J. Cwik, C. J. Detrisac, I. M. Kapetanovic, R. A. Lubet, J. A. Crowell, and D. L. McCormick
Subchronic Toxicity and Toxicogenomic Evaluation of Tamoxifen Citrate + Bexarotene in Female Rats
Toxicol. Sci., October 1, 2007; 99(2): 612 - 627.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Viswakarma, S. Yu, S. Naik, P. Kashireddy, K. Matsumoto, J. Sarkar, S. Surapureddi, Y. Jia, M. S. Rao, and J. K. Reddy
Transcriptional Regulation of Cidea, Mitochondrial Cell Death-inducing DNA Fragmentation Factor {alpha}-Like Effector A, in Mouse Liver by Peroxisome Proliferator-activated Receptor {alpha} and {gamma}
J. Biol. Chem., June 22, 2007; 282(25): 18613 - 18624.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. Schupp, J. C. Curtin, R. J. Kim, A. N. Billin, and M. A. Lazar
A Widely Used Retinoic Acid Receptor Antagonist Induces Peroxisome Proliferator-Activated Receptor-{gamma} Activity
Mol. Pharmacol., May 1, 2007; 71(5): 1251 - 1257.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition
Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics